Providers

Delgocitinib led to notable improvement by week 4, which may have helped improve longer-term treatment adherence.

As physician shortages and burnout threaten the patient experience in oncology, The US Oncology Network works to scale solutions, including the use AI ambient scribes and other workflow fixes, as well as fostering self-care strategies.

At NAACOS 2026, value-based care leaders make the case for treating payers as partners and explain what providers must see in return.

Pediatric care deserts push Medicaid families into costly ED visits; learn how primary care access gaps fuel chronic issues and spending.

Rani Bansal, MD, explores what's driving the surge in breast cancer in young women and why earlier, risk-based screening matters.

FDA grants lunsotogene parvec-cwha approval for OTOF-related hearing loss, delivering single-dose gene therapy gains and expanding access with free US supply.

Off-the-shelf cema-cel clears MRD at more than triple the rate of observation alone—and may propel a shift to frontline use of CAR T-cell therapy when relapse is hard to detect.

Results of 2 programs show what it takes to move social determinants of health from research into clinical practice—and what’s still missing.

DELTA 3 trial extension data show sustained improvements in disease-specific, dermatology-specific, and overall quality-of-life measures.

Previous inquiries into the associations between sleep disorders were limited by small sample sizes, according to researchers.

At 24 months, patients receiving iptacopan had approximately half the decline in estimated glomerular filtration rate slope compared to those receiving placebo.

Late diagnosis of hepatitis B and C remains common and is driven by factors like older age, male sex, comorbidities, and limited healthcare engagement.

Inconsistent use and wording of the “Not Better Explained” diagnostic criterion across major sleep disorder classifications may impact diagnostic accuracy, highlighting the need for greater standardization and clarity in clinical frameworks.

Patients who saw hair specialist dermatologists tended to be prescribed more therapies for their scarring alopecia.

EBO Editor in Chief Sucharu "Chris" Prakash, MD, addresses the role of nutrition in cancer prevention and treatment.

Todd Doyle, MD, of OneOncology, warns that commercial payers lag on updating bundled codes, which has slashed radiation oncology revenue and risks community cancer access in 2026.

Steven Kheloussi, PharmD, explains how care coordination and transparent policies can improve MS treatment adherence, streamline access, and balance costs.

Prior authorization and PBM utilization management delay oncology and hematology novel therapies, shifting reimbursement risk to patients in Medicare Advantage.

CHECK-US data show chronic hand eczema is driven by multiple triggers and linked to moderate disease severity and significant quality-of-life burden.

Tim Church, MD, PhD, MPH, explains that access to care—not willpower—is the central barrier to GLP-1 use, and says employer coverage decisions are finally catching up.

Lalan Wilfong, MD, a medical oncologist well known for his work in practice transformation, said he looks forward to creating "something more or less from scratch."

Cardiac MRI tissue characterization can detect early, low-burden transthyretin cardiac amyloidosis and accurately distinguish it from similar conditions, a study found.

Biologic-naïve status and higher inflammation predict rapid skin clearance with psoriasis biologics, while palmoplantar disease may limit response.

New strategies and therapies are being developed to try and decrease the risk of bone disease and cardiovascular complications among people with severe kidney disease.

Family caregivers absorb enormous burden after a breast cancer diagnosis, so routine caregiver support is vital.